DAX24.048 -0,2%Est505.865 +0,1%MSCI World4.343 -0,1%Top 10 Crypto9,8600 +2,9%Nas24.887 +0,2%Bitcoin65.675 -0,6%Euro1,1697 -0,2%Öl111,7 +3,1%Gold4.629 -1,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Siemens Energy ENER6Y SAP 716460 Deutsche Telekom 555750 Infineon 623100 Lufthansa 823212 Amazon 906866 NEL ASA A0B733 Siemens 723610 Mercedes-Benz Group (ex Daimler) 710000 Microsoft 870747 AMD (Advanced Micro Devices) 863186 Novo Nordisk A3EU6F Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX wenig bewegt -- Asiens Börsen in Rot -- Verdi ruft Deutsche Telekom zu ersten Warnstreiks auf -- BASF, Alphabet, Advantest, BP, Amazon, Tesla, VW, Bayer, QIAGEN im Fokus
Top News
BASF-Aktie dennoch im Plus: Analyst bleibt skeptisch BASF-Aktie dennoch im Plus: Analyst bleibt skeptisch
Disney-Aktie: Trump fordert nach Kimmel-Satire Entlassung des Moderators Disney-Aktie: Trump fordert nach Kimmel-Satire Entlassung des Moderators
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Halozyme Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
54,90 EUR -0,20 EUR -0,36 %
STU
64,84 USD +0,36 USD +0,56 %
nachbörslich
BTT
finanzen.net zero
Halozyme Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.6,62 Mrd. EUR

KGV26,31Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0DLHS

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS40637H1095

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolHALO

Halozyme Therapeutics Aktien News

DatumMeistgelesen
PR NewswireHalozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
PR NewswireHalozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
PR NewswireU.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
Wer­bungHalozyme Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireJim Lang Elected to Halozyme's Board of Directors
PR NewswireHalozyme to Participate in the 8th Annual Evercore Healthcare Conference
PR NewswireHalozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
PR NewswireMerus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
PR NewswireFDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
PR NewswireHALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme to Report Third Quarter 2025 Financial and Operating Results
PR NewswireHalozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
PR NewswireHalozyme to Participate at Upcoming Investor Conferences
PR NewswireHALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
PR NewswireEuropean Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
PR NewswireHalozyme to Report Second Quarter 2025 Financial and Operating Results
PR NewswireHalozyme Therapeutics Added to Russell 1000® Index
PR NewswireHalozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR NewswireHalozyme to Participate at Upcoming Investor Conferences
PR NewswireHalozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
PR NewswireHALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
PR NewswireHalozyme to Participate in the BofA Securities 2025 Healthcare Conference
PR NewswireHalozyme to Report First Quarter 2025 Financial and Operating Results
PR NewswireHalozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
PR NewswireHalozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinati...
PR NewswireEuropean Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
PR NewswireEuropean Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
PR NewswireHalozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
PR NewswireHalozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
PR NewswireHALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
PR NewswireHalozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
PR NewswireCHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
PR NewswireHalozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
PR NewswireHalozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
PR NewswireHalozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
PR NewswireHalozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
PR NewswireHalozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHalozyme nimmt Vorschlag über Zusammenschluss mit Evotec aufgrund fehlender Gesprächsbereitschaft von Evotec zurück
PR NewswireHalozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
PR NewswireHalozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Halozyme Therapeutics News

Halozyme Therapeutics News: auf dieser Seite finden Sie alle Halozyme Therapeutics News und Nachrichten zur Halozyme Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Halozyme Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Halozyme Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.